Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
Jump to section
Related Articles
Cited By...
- Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update
- Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment
- Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update
- Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey
- Review of current intracranial aneurysm flow diversion technology and clinical use
- Considerations for Antiplatelet Management of Carotid Stenting in the Setting of Mechanical Thrombectomy: A Delphi Consensus Statement
- Antiplatelet Management for Stent-Assisted Coiling and Flow Diversion of Ruptured Intracranial Aneurysms: A DELPHI Consensus Statement
- Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU)
- Predictive value of platelet reactivity unit (PRU) value for thrombotic and hemorrhagic events during flow diversion procedures: a meta-analysis
- Antiplatelet therapy and the risk of ischemic and hemorrhagic complications associated with Pipeline embolization of cerebral aneurysms: a systematic review and pooled analysis
- Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysis
- Procedural complexity independent of P2Y12 reaction unit (PRU) values is associated with acute in situ thrombosis in Pipeline flow diversion of cerebral aneurysms
- Early angiographic signs of acute thrombus formation following cerebral aneurysm treatment with the Pipeline embolization device
- P2Y12 hyporesponse (PRU>200) is not associated with increased thromboembolic complications in anterior circulation Pipeline